Name in SEC filings: Rani Therapeutics Holdings, Inc.
| Program | Event | Stage | Stated timing | Filing |
|---|---|---|---|---|
| RT-114 / PG-102 via RaniPill HC | /data readout | Stage not stated | by the end of 2026 | 8-K · |
| RT-114 / PG-102 via RaniPill HC | Topline/data readout | Stage not stated | 2027 | 10-Q · |
Source: ORION, orionbiotechai.com/company/RANI, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/RANI
RT-114 / PG-102 via RaniPill HC · Topline/data readout · by the end of 2026
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Topline/data readoutby the end of 2026
Stage: Not stated
Public float: $65,000,000 · as of · SEC filing
We have continued to advance the program in the clinic, with additional data from the dose expansion cohort expected by the end of 2026.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readout2027
Stage: Not stated
Public float: $65,000,000 · as of · SEC filing
The Phase 1b study will assess the safety, tolerability, and pharmacodynamic effect of eight weeks of repeat dosing with RT-114 in patients with obesity, and is expected to begin in 2026, with data anticipated in 2027.
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-12)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| RT-114 / PG-102 via RaniPill HCClinical results | by the end of 2026“We have continued to advance the program in the clinic, with additional data from the dose expansion cohort expected by the end of 2026.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| RT-114 / PG-102 via RaniPill HCClinical results | 2027“The Phase 1b study will assess the safety, tolerability, and pharmacodynamic effect of eight weeks of repeat dosing with RT-114 in patients with obesity, and is expected to begin in 2026, with data anticipated in 2027.” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Suggest an SEC timing statement to add for RANI. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See RANI in the calendar · Review labels and methodology